Product image of Letrozolo Pensa (Letrozole) supplied by GNH India

Letrozolo Pensa

Active Ingredient:
Letrozole
Origin:
EU

Letrozolo Pensa (Letrozole)

Letrozole, the active ingredient in Letrozolo Pensa, is an aromatase inhibitor presented as an oral tablet for oral use. It reduces estrogen production and is employed in the treatment of estrogen receptor‑positive breast cancer in postmenopausal women and is indicated for patients with advanced disease.

GNH India supplies Letrozolo Pensa as a licensed, GDP‑compliant international pharmaceutical product to hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network adheres to stringent quality standards and regulatory requirements, ensuring consistent product availability across multiple regions.

Manufacturer / TM Owner

Towa Pharmaceutical S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is used in hormone‑dependent breast cancer management, targeting estrogen‑driven tumor growth.

  • Early‑stage estrogen receptor‑positive breast cancer: improves disease‑free survival as adjuvant therapy.
  • Metastatic estrogen receptor‑positive breast cancer: delays progression in postmenopausal patients.
  • Neoadjuvant treatment of estrogen receptor‑positive breast cancer: reduces tumor size before surgery.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme (CYP19A1) in peripheral tissues, inhibiting the conversion of androstenedione and testosterone to estrone and estradiol. By lowering circulating estrogen levels, it deprives estrogen‑dependent tumor cells of a growth stimulus, thereby slowing or halting tumor proliferation in postmenopausal women. The inhibition is dose‑dependent and results in a sustained reduction of estrogen concentrations to less than 20 % of baseline within days.

Side Effects

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Hot flashes: transient episodes of increased skin temperature and sweating.
  • Joint and muscle pain: arthralgia or myalgia affecting daily activities.
  • Fatigue: persistent tiredness not relieved by rest.
  • Nausea: mild to moderate upset stomach.
  • Headache: occasional throbbing pain.
  • Increased cholesterol: mild elevation of serum lipid levels.

Serious or Rare Side Effects

  • Osteoporosis: decreased bone mineral density leading to fractures.
  • Severe liver injury: marked elevation of transaminases or hepatic failure.
  • Pulmonary embolism: sudden shortness of breath with chest pain.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Cardiovascular events: myocardial infarction or stroke.

Precautions & Warnings

When prescribing letrozole, clinicians should consider several safety and handling precautions.

  • Monitor bone health: assess baseline density and consider calcium/vitamin D supplementation.
  • Check liver function: perform periodic hepatic enzyme tests.
  • Assess lipid profile: monitor cholesterol levels during therapy.
  • Evaluate cardiovascular risk: review history of thromboembolic disease.
  • Counsel on menopausal symptoms: discuss management of hot flashes and mood changes.
  • Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Avoid Interactions

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole plasma levels.
  • Tamoxifen: concurrent use may antagonize therapeutic effect.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring.
  • Cholesterol‑lowering agents (statins): possible increase in statin concentrations.
  • SSRIs/SNRIs: may exacerbate mood changes or fatigue.
  • Herbal supplements containing St. John’s wort: may lower letrozole exposure.

Frequently Asked Questions

Letrozolo Pensa contains letrozole, an aromatase inhibitor indicated for the treatment of estrogen receptor‑positive breast cancer in postmenopausal women, including adjuvant, neoadjuvant and metastatic settings.

Letrozole blocks the aromatase enzyme, preventing the conversion of androgens to estrogen. The resulting drop in circulating estrogen deprives hormone‑sensitive tumor cells of a key growth signal, slowing disease progression.

The prescribed dose of letrozole is determined by the treating physician based on the patient’s clinical condition, disease stage and local prescribing guidelines. Patients should follow the exact regimen provided by their healthcare professional.

Letrozole is contraindicated in pregnancy and its safety during breastfeeding is not established. Women of child‑bearing potential should use effective contraception, and breastfeeding should be avoided while on therapy.

To place an order, submit an enquiry on the Letrozolo Pensa product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole, as a third‑generation aromatase inhibitor, typically offers more potent estrogen suppression than earlier agents like anastrozole. Compared with selective estrogen receptor modulators such as tamoxifen, letrozole does not act on the estrogen receptor directly but reduces estrogen levels, which can be advantageous in postmenopausal patients.

Letrozolo Pensa tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children.

Letrozolo Pensa is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water.

Serious risks include osteoporosis leading to fractures, severe liver injury, pulmonary embolism, and rare cardiovascular events such as myocardial infarction or stroke. Patients should be monitored regularly for bone health, liver function and signs of thromboembolic disease.

Letrozole should not be used in premenopausal women, pregnant or nursing individuals, and patients with known hypersensitivity to letrozole or any component of the formulation. Caution is advised in patients with severe liver impairment or uncontrolled cardiovascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT